Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month

Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine ...
ascopubs.org

Costs and Benefits of Whole-Exome, Whole-Transcriptome Sequencing in Patients With Advanced Non–Small Cell Lung Cancer

Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model–Based Prediction An economic model was developed to estimate the ...
ascopubs.org

Clinical Implementation of Expanded Solid Tumor Fusion Detection With Whole-Transcriptome Sequencing at an Academic Cancer Center

We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...

Caris Life Sciences (CAI) expands AI insights portfolio with signature to predict ovarian cancer platinum resistance

Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best NASDAQ stocks under $30 to buy. On March 16, Caris Life Sciences ...
Morningstar

Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

New chemistry reduces barriers to scaling single-cell studies across research settings Launch planned for March 2026, available across Evercode Whole Transcriptome product line Parse Biosciences, a ...
technologynetworks

How To Obtain Robust Whole Transcriptome Sequencing From FFPE Samples

Precision oncology is shifting toward comprehensive transcriptome profiling to reveal fusions, splice variants, and expression changes that DNA panels miss. Yet obtaining reliable data from degraded ...